Macular Photocoagulation Study Group, “Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration: Results of a Randomized Clinical Trial”, Archives of Ophthalmology 109, no. 9 (1991): 1220–1231.CrossRefGoogle Scholar

Miller, J.W., et al., “Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered Benzoporphyrin”, Archives of Ophthalmology 113, no. 6 (1995): 810–818; M. Kramer, et al., “Liposomal Benzoporphyrin Derivative Verteporfin Photodynamic Therapy: Selective Treatment of Choroidal Neovascularization in Monkeys”, Ophthalmology 103, no. 3 (1996): 427-438; D. Husain, et al., “Intravenous Infusion of Liposomal Benzoporphyrin Derivative for Photo-dynamic Therapy of Experimental Choroidal Neovasculariza-tion”, Archives of Ophthalmology 114, no. 8 (1996): 978-985.CrossRefGoogle ScholarPubMed

Verteporfin Roundtable 2000 and 2001 Participants et al., “Guidelines for Using Verteporfin (Visudyne) in Photody-namic Therapy to Treat Choroidal Neovascularization Due to Age-Related Macular Degeneration and Other Causes”, Retina 22, no. 1 (2002): 6–18.CrossRefGoogle Scholar

TAP Study Group, “Photodynamic Therapy of Subfoveal Cho-roidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: One-Year Results of 2 Randomized Clinical Trials”, Archives of Ophthalmology 117, no. 10 (1999): 1329–1345; N. M. Bressler, “Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: Two-Year Results of 2 Randomized Clinical Trials-Tap Report 2”, Archives of Ophthalmology 119, no. 2 (2001): 198-207; Verteporfin in Photodynamic Therapy Study, “Photodynamic Therapy of Subfoveal Choroidal Neo-vascularization in Pathologic Myopia with Verteporfin: 1-Year Results of a Randomized Clinical Trial — VIP Report no. 1”, Ophthalmology 108, no. 5 (2001): 841-852; Verteporfin In Photodynamic Therapy Study, “Verteporfin Therapy of Sub-foveal Choroidal Neovascularization in Age-Related Macular Degeneration: Two-Year Results of a Randomized Clinical Trial Including Lesions with Occult with no Classic Choroidal Neovascularization — Verteporfin in Photodynamic Therapy Report 2.” American Journal of Ophthalmology 131, no. 5 (2001): 541-560.CrossRefGoogle Scholar

Michaelson, I. C., “The Mode of Development of the Vascular System of the Retina, with Some Observations on its Significance for Certain Retinal Diseases”, Transactions of the Ophthalmological Societies of the United Kingdom 68 (1948): 137–180.Google Scholar

Gimbrone, M. A. Jr., et al., “Tumor Dormancy in Vivo by Prevention of Neovascularization”, Journal of Experimental Medicine 136, no. 2 (1972): 261–276.CrossRefGoogle ScholarPubMed

Folkman, J., “Tumor Angiogenesis: Therapeutic Implications”, New England Journal of Medicine 285, no. 21 (1971): 1182–1186.Google ScholarPubMed

Klagsbrun, M. M. and Moses, M.A., “Obituary: M. Judah Folk-man (1933-2008)”, Nature 451, no. 7180 (2008): 781.CrossRefGoogle Scholar

Leung, D. W., et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”, Science 246, no. 4935 (1989): 1306–1309.CrossRefGoogle ScholarPubMed

Keck, P. J., et al., “Vascular Permeability Factor, An Endothelial Cell Mitogen Related to PDGF”, Science 246, no. 4935 (1989): 1309–1312.CrossRefGoogle ScholarPubMed

Senger, D. R., et al., “Tumor Cells Secrete a Vascular Permeability Factor that Promotes Accumulation of Ascites Fluid”, Science 219, no. 4587 (1983): 983–985.CrossRefGoogle ScholarPubMed

Miller, J. W. et al., “Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model”, The American Journal of Pathology 145, no. 3 (1994): 574–584.Google Scholar

Aiello, L. P., et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders”, New England Journal of Medicine 331, no. 22 (1994): 1480–1487.CrossRefGoogle ScholarPubMed

Adamis, A. P. et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascular-ization in a Nonhuman Primate”, Archives of Ophthalmology 114, no. 1 (1996): 66–71.CrossRefGoogle Scholar

Tolentino, M. J. et al., “Vascular Endothelial Growth Factor is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman Primate”, Archives of Ophthalmology 114, no. 8 (1996): 964–970.CrossRefGoogle Scholar

Engler, C. B. et al., “Interferon Alpha-2a Treatment of Patients with Subfoveal Neovascular Macular Degeneration: A Pilot Investigation”, Acta Ophthalmologica 71, no. 1 (1993): 27–31; C. Ross et al., “IFN-Alpha Antibodies in Patients with Age-Related Macular Degeneration Treated with Recombinant Human IFN-Alpha2a”, Journal oflnterferon & Cytokine Research 22, no. 4 (2002): 421-426.CrossRefGoogle ScholarPubMed

Gragoudas, E. S. et al., “Pegaptanib for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 351, no. 27 (2004): 2805–2816.CrossRefGoogle ScholarPubMed

Miller, J. W. et al., “Photodynamic Therapy with Vertepor-fin for Choroidal Neovascularization Caused by Age-Related Macular Degeneration: Results of a Single Treatment in a Phase 1 and 2 Study”, Archives of Ophthalmology 117, no. 9 (1999): 1161–1173.CrossRefGoogle Scholar

Rosenfeld, P. J. et al., “Ranibizumab for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 355, no. 14 (2006): 1419–1431.CrossRefGoogle ScholarPubMed

Brown, D. M. et al., “Ranibizumab Versus Verteporfin for Neo-vascular Age-Related Macular Degeneration”, New England Journal of Medicine 355, no. 14 (2006): 1432–1444.CrossRefGoogle Scholar

Rosenfeld, P. J., Moshfeghi, A.A., and Puliafito, C.A., “Optical Coherence Tomography Findings after an Intravitreal Injection of Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”, Ophthalmic Surgical Lasers Imaging 36, no. 4 (2005): 331–335.CrossRefGoogle ScholarPubMed

CATT Research Group et al., “Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 364, no. 20 (2011): 1897–1908.CrossRefGoogle Scholar

Comparison of Age-related Macular Degeneration Treatments Trials Research Group et al., “Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results”, Ophthalmology 119, no. 7 (2012): 1388–1398.CrossRefGoogle Scholar

CATT Research Group et al., supra note 22; Id.Google Scholar

IVAN Study Investigators et al., “Ranibizumab Versus Bevaci-zumab to Treat Neovascular Age-Related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial”, Ophthalmology 119, no. 7 (2012): 1399–1411; U. Chakravarthy, et al., “Alternative Treatments to Inhibit VEGF in Age-Related Choroidal Neovascularisation: 2-year Findings of the IVAN Randomised Controlled Trial”, Lancet 382, no. 9900 (2013): 1258-1267.CrossRefGoogle Scholar

Verteporfin Roundtable, supra note 3.Google Scholar

Mass Eye and Ear Infirmary v. QLT Phototherapeutics, Inc., in 552, s. Cir., Editor. 2009, F.3d. p. 47, 57.Google Scholar

Adams, J. U., “Building the Bridge from Bench to Bedside”, Nature Reviews Drug Discovery 7, no. 6 (2008): 463–464.CrossRefGoogle Scholar

Id.Google Scholar

Mazzucato, M., “Mission-Oriented Innovation Policy: Challenges and Opportunites”, Industrial and Corporate Change 27, no. 5 (2018): 803–815.CrossRefGoogle Scholar